Premium
Migraine Prophylaxis with Salmon Calcitonin: a Cross‐over Double‐blind, Placebo‐controlled Study
Author(s) -
Gennari Carlo,
Chierichetti M. Silvio,
Gonnelli Stefano,
Vibelli Claudio,
Montagnani Mario,
Piolini Marco
Publication year - 1986
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.1986.hed2601013.x
Subject(s) - placebo , migraine , calcitonin , medicine , double blind , calcitonin gene related peptide , placebo group , anesthesia , neuropeptide , alternative medicine , receptor , pathology
SYNOPSIS Ten women with histories of migraine attacks and with diagnosis of classic or common migraineconcluded a double‐blind, placebo controlled, cross‐over study to assess the effectiveness of syntheticsalmon calcitonin 100 MRC U. i.m. a day in preventing migraine attacks. After a two‐month run‐in phase thewomen were randomly allocated to one of the following two‐month sequences: placebo‐calcitonin orcalcitonin‐placebo. The patients filled in every day a standard card with number, duration and severity ofattacks. The mean migraine frequency per month on calcitonin was 3.7±0.7 (s.e.m.) and on placebo 7.7±1.3(r<0.01). The ratio of total score of headache intensity to the number of days of observation on calcitoninwas 0.18±0.03 and on placebo was 0.30±0.04 (r<0.01). It is concluded that calcitonin is effective forprophylactic treatment of migraine and should be useful when other first‐choice treatments arecontraindicated.